Evidence map›Paper›PMID 38902947›Full record

ArticleJournal of the National Cancer Institute2024

Differences in tumor-associated T-cell receptor repertoires between early-onset and average-onset colorectal cancer.

Ya-Yu Tsai, Kanika G Nair, Shimoli V Barot, Shao Xiang, Suneel Kamath, Marilena Melas, Christopher P Walker, Raghvendra M Srivastava, Nicole Osborne, Timothy A Chan and 13 more

Abstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Challenges and future directions of AIRR-seq-based diagnostics.Immunoinformatics (Amsterdam, Netherlands) · 2025
    Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Ya-Yu TsaiGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Kanika G NairCleveland Clinic Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, OH, USA.
Shimoli V BarotDepartment of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA.
Shao XiangDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, USA.
Suneel KamathCleveland Clinic Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, OH, USA.
Marilena MelasNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Christopher P WalkerDepartment of Medical Oncology and Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, USA.
Raghvendra M SrivastavaCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA.
Nicole OsborneCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA.
Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA.
Jonathan B MitchemDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, USA.
Joseph D BonnerDepartment of Medical Oncology and Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, USA.
Kevin J McDonnellDepartment of Medical Oncology and Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, USA.
Gregory E IdosDepartment of Medical Oncology and Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, USA.
Rebeca Sanz-PamplonaCatalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain.
Joel K GreensonUniversity of Michigan, Ann Arbor, MI, USA.
Hedy S RennertB. Rappaport Faculty of Medicine, Technion and the Association for Promotion of Research in Precision Medicine (APRPM), Haifa, Israel.
Gad RennertB. Rappaport Faculty of Medicine, Technion and the Association for Promotion of Research in Precision Medicine (APRPM), Haifa, Israel.ORCID 0000-0002-8512-068X
Victor MorenoCatalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0002-2818-5487
Stephen B GruberDepartment of Medical Oncology and Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, USA.
Alok A KhoranaCleveland Clinic Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, OH, USA.
David LiskaCleveland Clinic Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, OH, USA.
Stephanie L SchmitGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0001-5931-1194

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
MOLECULAR EPIDEMIOLOGY OF COLORECTAL CANCERR01CA081488 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GRUBER, STEPHEN B · 1999 to 2008
$9.2M
TOWARDS PRECISION IMMUNO-ONCOLOGY: UNRAVELING THE GENOMIC DETERMINANTS AND MECHANISMS UNDERLYING IMMUNOTHERAPY EFFICACY AND RESISTANCER35CA232097 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHAN, TIMOTHY AN-THY · 2018 to 2024
$7.0M
Variation in tumor-associated immune profiles and colorectal cancer outcomesR01CA248931 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI SCHMIT, STEPHANIE L. · 2021 to 2025
$3.5M
Integration of epidemiology, pathology, immunology and outcomes in colorectal cancerR01CA263318 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI STEPHEN B GRUBER · 2022 to 2026
$3.4M
The Epidemiology of Immune Responses in Colorectal CancerR01CA197350 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GRUBER, STEPHEN B · 2015 to 2019
$3.2M
Agency for Management of University and Research 2017SGR723Instituto de Salud Carlos III PI17-00092NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA081488NCI NIH HHS R01 CA197350NCI NIH HHS R01 CA248931NCI NIH HHS R01 CA263318NCI NIH HHS R35 CA232097Scientific Foundation GCTRA18022MORESpanish Association Against Cancer
6 · The paper itself

Abstract

The incidence of colorectal cancer (CRC) among individuals younger than age 50 (early-onset CRC [EOCRC]) has substantially increased, and yet the etiology and molecular mechanisms underlying this alarming rise remain unclear. We compared tumor-associated T-cell repertoires between EOCRC and average-onset CRC (AOCRC) to uncover potentially unique immune microenvironment-related features by age of onset. Our discovery cohort included 242 patients who underwent surgical resection at Cleveland Clinic from 2000 to 2020. EOCRC was defined as younger than age 50 years at diagnosis (N = 126) and AOCRC as 60 years of age or older (N = 116). T-cell receptor (TCR) abundance and clonality were measured by immunosequencing of tumors. Logistic regression models were used to evaluate the associations between TCR repertoire features and age of onset, adjusting for sex, race, tumor location, and stage. Findings were replicated in 152 EOCRC and 1984 AOCRC cases from the Molecular Epidemiology of Colorectal Cancer Study. EOCRC tumors had significantly higher TCR diversity compared with AOCRC tumors in the discovery cohort (odds ratio [OR] = 0.44, 95% confidence interval [CI] = 0.32 to 0.61, P < .0001). This association was also observed in the replication cohort (OR = 0.74, 95% CI = 0.62 to 0.89, P = .0013). No significant differences in TCR abundance were observed between EOCRC and AOCRC in either cohort. Higher TCR diversity, suggesting a more diverse intratumoral T-cell response, is more frequently observed in EOCRC than AOCRC. Further studies are warranted to investigate the role of T-cell diversity and the adaptive immune response more broadly in the etiology and outcomes of EOCRC.

Indexed as

Age of OnsetColorectal NeoplasmsReceptors, Antigen, T-CellAdultAgedFemaleHumansMaleMiddle AgedTumor MicroenvironmentReceptors, Antigen, T-Cell

Identifiers

PMID38902947
PMCPMC12116298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.